Bone is an endocrine organ that reaches out to other tissues, orchestrating responses that may have a role in pathology and physiology at distant sites. In 'Bench to Bedside', L. Darryl Quarles discusses recent studies showing how a feedback loop between the bone hormone FGF-23 and renal phosphate excretion and vitamin D metabolism is integrated with the classical PTH-vitamin D axis in chronic kidney disease (CKD). This new paradigm may change the diagnosis and treatment of disordered mineral homeostasis of people with CKD. A recent epidemiological study argues a mechanistic link between bone loss and atherosclerosis, maladies usually linked to aging. In 'Bedside to Bench', Sundeep Khosla discusses how this clinical study underpins research showing that mediators of inflammation and oxidative stress share common mechanisms that may lead to this calcium shift during aging.
Bone is a metabolically active tissue regulated by multiple hormones that control formation and resorption to maintain bone mass and mineral homeostasis. But bone is also an endocrine organ that secretes osteocalcin to regulate glucose homeostasis and energy metabolism by targeting G proteincoupled receptor family C group 6 member A (GPRC6A) in beta cells and other tissues 1 , and fibroblast growth factor-23 (FGF-23), which is a recently discovered phosphate-and vitamin D-regulating hormone 2 .
FGF-23, which is predominately expressed in osteoblasts and osteocytes, targets FGF receptor-a-klotho complexes in the kidney, leading to inhibition of renal phosphate reabsorption and a decrease in circulating concentrations of 1,25(OH) 2 D, the active form of vitamin D, owing to decreased production by cytochrome P450, family 27, subfamily B, polypeptide 1 (Cyp27b1) and increased catabolism by Cyp24, enzymes that respectively hydroxylate 25(OH) D to active 1,25(OH) 2 In the pathological setting, FGF-23 has a role in hereditary hypophosphatemic disorders and tumor-induced osteomalacia, where excess FGF-23 results in hypophosphatemia, aberrant vitamin D metabolism and defective bone mineralization that leads to rickets and osteomalacia 2 . Physiologically, however, FGF-23 participates in a regulatory 1,25(OH) 2 D feedback loop-1,25(OH) 2 D stimulates FGF-23 production in bone and FGF-23 suppresses 1,25(OH) 2 D production by the kidney 3 -which may protect the organism from vitamin D intoxication (Fig. 1) . But how the FGF-23 bone-kidney axis is integrated with the classical parathyroid hormone endocrine axis, which principally functions to maintain serum calcium in a narrow range but also regulates 1,25(OH) 2 D production and renal phosphate reabsorption, is not fully understood.
Initial studies showed that parathyroid hormone does not directly stimulate FGF-23 production or FGF-23 promoter activity in osteoblasts in vitro 3 or in calvarial cultures ex vivo 4 and that parathyroid hormone administration suppresses circulating FGF-23 levels in normal mice 5 . FGF-23 levels are also not elevated in people with primary hyperparathyroidism, but there is evidence for indirect upregulation of FGF-23 by parathyroid hormone-mediated increase of 1,25(OH) 2 D levels 3 . A role for vitamin D signaling in parathyroid hormone regulation of FGF-23 is supported by the finding that vitamin D receptor-deficient mice have very high levels of parathyroid hormone but low FGF-23 levels.
Studies of the interplay between alterations in FGF-23 expression and disordered mineral metabolism in both animal models and humans with chronic kidney disease (CKD), however, reveal more complex interrelationships between parathyroid hormone, FGF-23 and vitamin D metabolism.
FGF-23 is markedly elevated in end-stage renal disease, and this correlates with the degree of hyperphosphatemia 6 , predicts refractory hyperparathyroidism 7 and is associated with increased mortality. Cross-sectional studies of people with less advanced CKD have shown that FGF-23 is an early marker of renal dysfunction that correlates with increased parathyroid hormone levels and decreased circulating amounts of 1,25(OH) 2 D (ref. 8 ).
Efforts to establish which comes first-FGF-23 or parathyroid hormone-has led to two competing concepts regarding the pathogenesis of disordered mineral metabolism in CKD.
On the one hand, FGF-23 may be the initial hormonal adaptive response in CKD leading to secondary hyperparathyroidism. In a rat model of anti-glomerular basement membrane nephritis, Hasegawa et al. 9 showed that treatment with a neutralizing antibody to FGF-23 increased serum 1,25(OH) 2 D concentration, along with increased Cyp27b1 and reduced Cyp24 expression, and suppressed parathyroid hormone levels, showing that FGF-23 is the initial and primary factor, leading to secondary reductions in 1,25(OH)2D and elevations in parathyroid hormone.
These findings challenge the traditional view that CKD is a vitamin D-deficient state and raises questions about current treatments for CKD that suppress parathyroid hormone with active vitamin D analogs, which, in fact, can further elevate FGF-23 expression. These results, however, are consistent with the notion that FGF-23-mediated suppression of circulating 1,25(OH) 2 D levels is an adaptive response that protects against hyperphosphatemia, as decreasing 1,25(OH) 2 D limits gastrointestinal phosphate absorption and leads to increased parathyroid hormone secretion, which in concert with FGF-23 stimulates phosphaturia to maintain neutral phosphate balance in the setting of declining renal function (Fig. 1) .
On the other hand, there is equally compelling evidence supporting that parathyroid hormone is responsible for elevated FGF-23 expression in CKD. There is also a strong association between increased amounts of FGF-23 and the severity of hyperparathyroidism in CKD, and parathyroidectomy reduces FGF-23 levels in people with CKD 10 . FGF-23 expression is also increased in McCune-Albright Moreover, Lavi-Moshayoff et al. 12 recently showed that parathyroid hormone increases FGF23 expression and mediates the high FGF-23 abundance in an induced CKD model in rats. In this study, early parathyroidectomy prevented the increase in FGF-23 levels in rats with adenine-induced renal failure, and continuous parathyroid hormone administration at high doses stimulated FGF-23 production in mice and FGF-23 expression in UMR-106 osteoblasts in vitro. Parathyroid hormonestimulated FGF-23 expression, however, may be an indirect consequence of alterations in bone remodeling, as it was inhibited by disruption of Wnt signaling with sclerostin 12 .
Given these and other findings, the authors purport the existence of a parathyroid glandbone axis 13 : parathyroid hormone stimulates FGF-23 production in the bone, and FGF-23 feeds back on the parathyroid gland to inhibit parathyroid hormone secretion in healthy individuals. FGF-23-mediated suppression of parathyroid hormone is hampered in CKD, owing to the decrease in FGFR1 and a-klotho in the parathyroid glands, leading to an increase in parathyroid hormone in spite of concurrent increments in FGF-23 (ref. 13) .
Resolution of these conflicting concepts will require further studies. However, another function of FGF-23, to coordinate renal phosphate handling to balance bone mineralization and remodeling 2 , may help reconcile the divergent data regarding FGF-23 and parathyroid hormone regulation and function in CKD. Consistent with a modulating effect of bone remodeling on FGF-23 release, intermittent and continuous parathyroid hormone administration in mouse models respectively suppresses and stimulates FGF-23 and correlates with the differential anabolic and catabolic responses to parathyroid hormone 5 .
Similarly, parathyroid hormone induction of high bone turnover (osteitis fibrosa) in CKD might lead to increased production of FGF-23, analogous to the catabolic effects of continuous parathyroid hormone administration. If so, elevations of circulating FGF-23, which enhances renal phosphate excretion and reduces 1,25(OH) 2 D abundance by stimulating Cyp24-mediated catabolism, might be the initial response to the loss of glomerular filtration, which orchestrates a coordinated and progressive adaptation to protect the organism from the adverse effects of excess phosphate retention. As renal failure advances, secondary effects of elevated parathyroid hormone caused by FGF-23-mediated suppression of 1,25(OH) 2 D protect the organism from hypocalcemia and further stimulate FGF-23 production to work in concert with parathyroid hormone to further increase phosphate excretion, which aims to compensate for progressive reductions in renal function and increased phosphate efflux from bone caused by excessive bone turnover (Fig. 1) .
There are several clinical implications for these new mechanistic insights into the FGF-23 bone-kidney axis. FGF-23 may be a useful early marker for abnormal mineral metabolism in CKD. Understanding that treatment with active vitamin D analogs further increases FGF-23 levels, which is independently associated with increased mortality 14 , may support phosphate restriction in individuals with early-stage CKD, therapeutic efforts to normalize bone remodeling and mineralization and the use of treatment regimens that limit the dose of active vitamin D analogs in latestage CKD 15 .
Moreover Finally, as phosphate metabolism is important in energy metabolism, crosstalk between skeletal regulation of energy, phosphate and vitamin D metabolism may occur. For example, leptin stimulates FGF-23 expression, blocks bone remodeling 16 and may inhibit the osteocalcin-insulin endocrine loop regulating energy metabolism 1 .
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Aging is associated with calcium loss from bone and increased calcium deposition in blood vessels, but whether this shift in calcium is due to common pathogenetic mechanisms shared by osteoporosis and atherosclerosis or whether these diseases are merely comorbidities of aging has been unclear. For example, women with osteoporosis have a fourfold increased risk of cardiovascular events as compared to women without osteoporosis 1 . But whether this is due to a true association between these diseases independent of age has been unclear, as both osteoporosis and atherosclerosis become clinically evident starting in the sixth decade, and their incidence increases further with aging. Both diseases also affect multiple ethnic groups and both sexes, although osteoporosis is more common in women than in men. A recent epidemiological study from the Multi-Ethnic Study of Atherosclerosis (MESA) by Hyder et al. 2 is of particular interest, as their results indicate that osteoporosis and atherosclerosis are closely related, independent of age and other confounders. The authors used quantitative computed tomography in 946 women and 963 men, each with a mean age of approximately 65 years, to assess lumbar spine volumetric bone mineral density (LS-vBMD), an index of skeletal mass, as well as coronary artery calcium (CAC) and abdominal aortic calcium (AAC) scores, which are indices of atherosclerosis. After adjusting the data for age, ethnicity, body mass index, hypertension, dyslipidemia, diabetes mellitus, smoking, alcohol consumption, physical activity, inflammatory biomarkers (interleukin-6 (IL-6), C-reactive protein and homocysteine) and sex hormones, decreased LS-vBMD was significantly associated with increased CAC score among women and increased AAC score among both women and men. Adjusting statistically for these multiple variables was crucial to show a potential direct link between LS-vBMD and CAC and AAC scores independent of other variables that may be affecting both bone loss and atherosclerosis.
These findings are clinically relevant, as bone density is a well-established predictor of fracture risk 3 , and arterial calcium content increases the risk of cardiovascular events such as myocardial infarction and stroke, as well as of death from cardiovascular disease 4 . Notably, the results of this study show that the relationship between vBMD and vascular calcification scores was still present after adjustment for multiple confounding variables; however, whereas epidemiological studies such as this can generate plausible hypotheses, they cannot establish causality.
What, then, are the possible mechanistic links between bone loss and vascular disease? This question is best addressed after perusing the hitherto identified mechanisms underlying both bone and vascular remodeling. Bone is constantly modified through resorption by osteoclasts and formation by osteoblasts (Fig. 1) , a remodeling process that is triggered by osteocytes-osteoblast-lineage cells embedded in bone-that respond to local injury, such as a microcrack occurring during normal loading, and serve an important repair function. Increasing evidence indicates that bone remodeling occurs in the bone remodeling compartment, a closed cavity covered by a canopy of bone-lining cells (probably quiescent osteoblasts) that is penetrated by a capillary that provides perivascular progenitor cells that differentiate into functional osteoblasts 5 .
The atherosclerotic plaque shows striking similarities with the bone remodeling compartment (Fig. 1) . A crucial point is that one of the outcomes of the remodeling processes within the plaque is calcium deposition, which not only is a marker for atherosclerosis but also may contribute to plaque instability and rupture, resulting in myocardial infarction 6 . Why, then, is vascular calcification associated with bone loss, as demonstrated by Hyder et al. 2 ?
Although numerous factors regulate both bone and vascular calcification, such as receptor activator of nuclear factor-kB ligand (RANKL), osteoprotegerin (OPG), matrix gla protein (MGP) and osteopontin 5, 7 , there are two pathways that are activated with aging and can lead simultaneously to bone loss and vascular calcification: inflammation and oxidative stress, pathways that may therefore be potential candidates for linking osteoporosis and atherosclerosis.
There is considerable evidence showing that the production of inflammatory cyto kines, such as tumor necrosis factor-a (TNF-a) and IL-1b, by cells in the bone microenvironment, including osteoblasts and T cells, leads to increased resorption and decreased formation 8 . These effects are mediated, in part, via cytokine-induced increases in RANKL, a key stimulator of bone resorption, by osteoblasts and T cells, among other cell types 8 . TNF-a is also an inhibitor of bone formation 8 , tilting the balance toward bone resorption with subsequent bone loss. In the vasculature, however, TNF-a and other inflammatory cytokines may drive the development of an osteogenic phenotype by vascular smooth muscle cells and other progenitor cells, such as pericytes, in the vessel wall, in part through the activation of the Msx2-Wnt-b-catenin signaling cascade, which is also involved in normal bone formation 9 .
Sex steroid deficiency, which occurs abruptly after the menopause in women and more gradually with aging in men, is a potent stimulus to bone loss 8 . Loss of sex steroids results in increased amounts of RANKL in bone, in part by inducing inflammatory cytokine production by osteoblasts and T cells, and decreased
